keyword
MENU ▼
Read by QxMD icon Read
search

Immunomodulatory agents

keyword
https://www.readbyqxmd.com/read/28096298/mfg-e8-derived-peptide-attenuates-adhesion-and-migration-of-immune-cells-to-endothelial-cells
#1
Yohei Hirano, Weng-Lang Yang, Monowar Aziz, Fangming Zhang, Barbara Sherry, Ping Wang
Milk fat globule-epidermal growth factor-factor 8 (MFG-E8) plays an immunomodulatory role in inflammatory diseases. MFG-E8-derived short peptide (MSP68) greatly reduces neutrophil infiltration and injury in the lung during sepsis. In this study, we examined the effect of MSP68 on chemotaxis of various immune cells and its regulatory mechanism. Bone marrow-derived neutrophils (BMDNs) from C57BL/6 mice, human monocyte THP-1 cell line, and human T lymphocyte Jurkat cell line were used for adhesion and migration assays using a Transwell method in the presence of MSP68...
January 17, 2017: Journal of Leukocyte Biology
https://www.readbyqxmd.com/read/28094770/rapamycin-mediated-mtor-inhibition-uncouples-hiv-1-latency-reversal-from-cytokine-associated-toxicity
#2
Alyssa R Martin, Ross A Pollack, Adam Capoferri, Richard F Ambinder, Christine M Durand, Robert F Siliciano
Current strategies for HIV-1 eradication require the reactivation of latent HIV-1 in resting CD4+ T cells (rCD4s). Global T cell activation is a well-characterized means of inducing HIV-1 transcription, but is considered too toxic for clinical applications. Here, we have explored a strategy that involves a combination of immune activation and the immunosuppressive mTOR inhibitor rapamycin. In purified rCD4s from HIV-1-infected individuals on antiretroviral therapy, rapamycin treatment downregulated markers of toxicity, including proinflammatory cytokine release and cellular proliferation that were induced after potent T cell activation using αCD3/αCD28 antibodies...
January 17, 2017: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/28093713/timing-of-future-remyelination-therapies-and-their-potential-to-stop-multiple-sclerosis-progression
#3
Burcu Zeydan, Moses Rodriguez, Orhun H Kantarci
Prior to the onset of demyelination in multiple sclerosis (MS), early oligodendrocyte injury, axonal degeneration and astroglial scarring occur. The irreversible progressive phase of MS begins when the axonal loss threshold is reached. Progressive disease onset has the highest impact on a poor prognosis in MS. Conversion to progressive disease is essentially an age-dependent process independent of disease duration and initial disease course. Although prevention of relapses has been the primary approach in the disease management, incomplete recovery from even the first relapse correlates with the long-term neurodegenerative phenotype of progressive MS onset...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28092065/impact-of-celecoxib-on-inflammation-during-cancer-surgery-a-randomized-clinical-trial
#4
Jonathan G Hiller, Shienny Sampurno, Rosemary Millen, Niketh Kuruvilla, Kwok M Ho, Rob Ramsay, Bernhard Riedel
PURPOSE: During cancer surgery, prostaglandin-mediated inflammation may promote and activate micrometastatic disease with a consequent increase in long-term cancer recurrence. Cyclooxygenase-2 inhibitors, known to have anti-proliferative properties, may offset such perioperative perturbation. We investigated the effectiveness of these agents to minimize inflammatory changes during cancer surgery. METHODS: Following ethics approval, 32 patients who were to undergo major intracavity cancer surgery were enrolled in this prospective, randomized, clinical trial...
January 13, 2017: Canadian Journal of Anaesthesia, Journal Canadien D'anesthésie
https://www.readbyqxmd.com/read/28078989/a-comprehensive-review-of-mtor-inhibiting-pharmacotherapy-for-the-treatment-of-non-infectious-uveitis
#5
Joshua Blair, Robert Barry, David J Moore, Alastair K Denniston
BACKGROUND: Non-infectious uveitis is a sight-threatening inflammatory disease that often necessitates prolonged use of high-dose corticosteroids, resulting in significant systemic side effects. There is a need for efficacious steroid-sparing immunomodulatory therapy for these patients, and the mTOR inhibitors (sirolimus and everolimus) may be contenders for this role. METHODS: A comprehensive review of preclinical and clinical research on mTOR inhibitors for non-infectious uveitis was performed...
January 11, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28071679/novel-long-chain-compounds-with-both-immunomodulatory-and-mena-inhibitory-activities-against-staphylococcus-aureus-and-its-biofilm
#6
Seoung-Ryoung Choi, Joel Frandsen, Prabagaran Narayanasamy
Menaquinone (MK) biosynthesis pathway is a potential target for evaluating antimicrobials in gram-positive bacteria. Here, 1,4-dihydroxy-2-naphthoate prenyltransferase (MenA) was targeted to reduce methicillin-resistant Staphylococcus aureus (MRSA) growth. MenA inhibiting, long chain-based compounds were designed, synthesized and evaluated against MRSA and menaquinone utilizing bacteria in aerobic conditions. The results showed that these bacteria were susceptible to most of the compounds. Menaquinone (MK-4) supplementation rescued MRSA growth, suggesting these compounds inhibit MK biosynthesis...
January 10, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28062696/prostaglandin-e2-inhibition-of-il-27-production-in-murine-dendritic-cells-a-novel-mechanism-that-involves-irf1
#7
Kirsten M Hooper, Jui-Hung Yen, Weimin Kong, Kate M Rahbari, Ping-Chang Kuo, Ana M Gamero, Doina Ganea
IL-27, a multifunctional cytokine produced by APCs, antagonizes inflammation by affecting conventional dendritic cells (cDC), inducing IL-10, and promoting development of regulatory Tr1 cells. Although the mechanisms involved in IL-27 induction are well studied, much less is known about the factors that negatively impact IL-27 expression. PGE2, a major immunomodulatory prostanoid, acts as a proinflammatory agent in several models of inflammatory/autoimmune disease, promoting primarily Th17 development and function...
January 6, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28058501/-cytokine-neutralization-at-specific-cellular-source-a%C3%A2-new-therapeutic-paradigm-german-version
#8
A A Kruglov, S A Nedospasov
BACKGROUND: Currently, treatment of autoimmune diseases is based on manipulation of general control mechanisms, including those mediated by immunoregulatory cytokines. This approach is non-curative and may cause unwanted side effects due to numerous beneficial and non-redundant functions of a particular cytokine. METHODS: Techniques of reverse genetics, such as conditional gene targeting, were employed to uncover the contributions of two proinflammatory and immunomodulatory cytokines, tumour necrosis factor (TNF) and interleukin 6 (IL-6), in various disease states...
January 5, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28057928/predictive-screening-of-m1-and-m2-macrophages-reveals-the-immunomodulatory-effectiveness-of-post-spinal-cord-injury-azithromycin-treatment
#9
John C Gensel, Timothy J Kopper, Bei Zhang, Michael B Orr, William M Bailey
Spinal cord injury (SCI) triggers a heterogeneous macrophage response that when experimentally polarized toward alternative forms of activation (M2 macrophages) promotes tissue and functional recovery. There are limited pharmacological therapies that can drive this reparative inflammatory state. In the current study, we used in vitro systems to comprehensively defined markers of macrophages with known pathological (M1) and reparative (M2) properties in SCI. We then used these markers to objectively define the macrophage activation states after SCI in response to delayed azithromycin treatment...
January 6, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28056758/thrombotic-management-of-antiphospholipid-syndrome-towards-novel-targeted-therapies
#10
Md Asiful Islam, Fahmida Alam, Kah Keng Wong, Mohammad Amjad Kamal, Siew Hua Gan
Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombosis and/or pregnancy morbidity with persistent levels of antiphospholipid antibodies (aPLs). The development of thrombosis in APS is mediated by aPLs and contributes to the high mortality rate in APS patients. However, although APS has been reported for more than 30 years, there has been no optimal regimen for its prevention or for the management of thrombosis, mainly because the mainstay treatment strategies for managing APS are not targeted towards aPL-mediated thrombotic pathophysiology...
5, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28056114/diagnosis-and-management-of-waldenstr%C3%A3-m-macroglobulinemia-mayo-stratification-of-macroglobulinemia-and-risk-adapted-therapy-msmart-guidelines-2016
#11
Prashant Kapoor, Stephen M Ansell, Rafael Fonseca, Asher Chanan-Khan, Robert A Kyle, Shaji K Kumar, Joseph R Mikhael, Thomas E Witzig, Michelle Mauermann, Angela Dispenzieri, Sikander Ailawadhi, A Keith Stewart, Martha Q Lacy, Carrie A Thompson, Francis K Buadi, David Dingli, William G Morice, Ronald S Go, Dragan Jevremovic, Taimur Sher, Rebecca L King, Esteban Braggio, Ann Novak, Vivek Roy, Rhett P Ketterling, Patricia T Greipp, Martha Grogan, Ivana N Micallef, P Leif Bergsagel, Joseph P Colgan, Nelson Leung, Wilson I Gonsalves, Yi Lin, David J Inwards, Suzanne R Hayman, Grzegorz S Nowakowski, Patrick B Johnston, Steven J Russell, Svetomir N Markovic, Steven R Zeldenrust, Yi L Hwa, John A Lust, Luis F Porrata, Thomas M Habermann, S Vincent Rajkumar, Morie A Gertz, Craig B Reeder
Importance: Waldenström macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, has witnessed several practice-altering advances in recent years. With availability of a wider array of therapies, the management strategies have become increasingly complex. Our multidisciplinary team appraised studies published or presented up to December 2015 to provide consensus recommendations for a risk-adapted approach to WM, using a grading system. Observations: Waldenström macroglobulinemia remains a rare, incurable cancer, with a heterogeneous disease course...
January 5, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28053544/nab-paclitaxel-as-a-potential-partner-with-checkpoint-inhibitors-in-solid-tumors
#12
REVIEW
Hatem H Soliman
Tumors recognized by the host immune system are associated with better survival. However, the immune system is often suppressed in patients with established tumor burden. Stimulating the immune system to detect and kill tumor cells has been a challenge in cancer therapy for some time. Recently, novel cancer immunotherapies, such as immune checkpoint inhibitors, monoclonal antibodies, and vaccine therapies, have emerged as promising therapeutic approaches for many solid tumors. However, for some tumors, immunotherapy alone has not provided significant benefits, and some may even be fully resistant to immunotherapy...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28053314/comparative-transcriptome-profiles-of-human-blood-in-response-to-the-toll-like-receptor-4-ligands-lipopolysaccharide-and-monophosphoryl-lipid-a
#13
Liming Luan, Naeem K Patil, Yin Guo, Antonio Hernandez, Julia K Bohannon, Benjamin A Fensterheim, Jingbin Wang, Yaomin Xu, Perenlei Enkhbaatar, Ryan Stark, Edward R Sherwood
Monophosphoryl lipid A (MPLA), a less toxic derivative of lipopolysaccharide (LPS), is employed as a vaccine adjuvant and is under investigation as a non-specific immunomodulator. However, the differential response of human leukocytes to MPLA and LPS has not been well characterized. The goal of this study was to compare the differential transcriptomic response of human blood to LPS and MPLA. Venous blood from human volunteers was stimulated with LPS, MPLA or vehicle. Gene expression was determined using microarray analysis...
January 5, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28050137/emerging-therapies-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma
#14
REVIEW
D MacDonald, A Prica, S Assouline, A Christofides, T Lawrence, L H Sehn
With no treatment standard having been established for relapsed and refractory follicular lymphoma, a number of therapeutic approaches are used in Canada. In patients who relapse early or who eventually become resistant to subsequent treatment, prognosis is poor, and new approaches are needed. A number of novel therapies are being examined in this setting, including monoclonal antibodies, immunoconjugates, immunomodulatory agents, and signal transduction inhibitors. With the body of evidence for those emerging therapies accumulating and the standard upfront treatment changing from rituximab and chop (cyclophosphamide-doxorubicin-vincristine-prednisone) or rituximab and cvp (cyclophosphamide-vincristine-prednisone) to bendamustine and rituximab, treatment decisions in the relapsed and refractory setting have become more complex...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28048670/tu-fg-brc-01-cancer-and-the-immune-system-the-basics
#15
E Repasky
: There is substantial current interest in the potential of radiation therapy for synergizing with novel immunotherapies to transform irradiated tumor into an immunogenic hub with capacity to ignite a powerful and adaptive longterm anti-cancer response. Interest stems from new insights into fundamental mechanisms underlying interactions between cancer, radiation and the immune system. Radically new immunotherapy approaches have been proposed, which target the immune system, rather than the cancer itself...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28048588/tu-fg-brc-04-opportunities-for-medical-physics-contributions-to-radiation-immunotherapy
#16
M Oldham
: There is substantial current interest in the potential of radiation therapy for synergizing with novel immunotherapies to transform irradiated tumor into an immunogenic hub with capacity to ignite a powerful and adaptive longterm anti-cancer response. Interest stems from new insights into fundamental mechanisms underlying interactions between cancer, radiation and the immune system. Radically new immunotherapy approaches have been proposed, which target the immune system, rather than the cancer itself...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28048005/tu-fg-brc-02-radiation-therapy-to-ignite-an-anti-cancer-immune-response
#17
S Formenti
: There is substantial current interest in the potential of radiation therapy for synergizing with novel immunotherapies to transform irradiated tumor into an immunogenic hub with capacity to ignite a powerful and adaptive longterm anti-cancer response. Interest stems from new insights into fundamental mechanisms underlying interactions between cancer, radiation and the immune system. Radically new immunotherapy approaches have been proposed, which target the immune system, rather than the cancer itself...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28047342/tu-fg-brc-03-current-clinical-trials-using-radiation-and-immunomodulatory-agents
#18
N Coleman
: There is substantial current interest in the potential of radiation therapy for synergizing with novel immunotherapies to transform irradiated tumor into an immunogenic hub with capacity to ignite a powerful and adaptive longterm anti-cancer response. Interest stems from new insights into fundamental mechanisms underlying interactions between cancer, radiation and the immune system. Radically new immunotherapy approaches have been proposed, which target the immune system, rather than the cancer itself...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28046619/tu-fg-brc-00-radiation-and-immunotherapy-how-to-ignite-long-term-anti-cancer-response
#19
Mark Oldham
: There is substantial current interest in the potential of radiation therapy for synergizing with novel immunotherapies to transform irradiated tumor into an immunogenic hub with capacity to ignite a powerful and adaptive longterm anti-cancer response. Interest stems from new insights into fundamental mechanisms underlying interactions between cancer, radiation and the immune system. Radically new immunotherapy approaches have been proposed, which target the immune system, rather than the cancer itself...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28043164/current-treatment-options-and-investigational-drugs-for-waldenstrom-s-macroglobulinemia
#20
Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis, Meletios A Dimopoulos
Waldenström's Macroglobulinemia (WM) is a rare, indolent, incurable, low-grade B-cell lymphoplasmacytic neoplasm. This review article provides a modern clinical perspective of the individualized management of patients with symptomatic WM, in the context of the updated treatment guidelines and the currently available trial data. Areas covered: Rituximab-based regimens (such as the dexamethasone, rituximab and cyclophosphamide combination, DRC) are the most widely used in the management of both newly diagnosed and relapsed/refractory patients with WM...
January 3, 2017: Expert Opinion on Investigational Drugs
keyword
keyword
82412
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"